120
Participants
Start Date
April 4, 2024
Primary Completion Date
March 31, 2026
Study Completion Date
April 30, 2026
Sovilnesib
Sovilnesib tablets will be given orally.
Icahn School of Medicine at Mount Sinai, New York
Roswell Park Comprehensive Cancer Center, Buffalo
Johns Hopkins Hospital, Baltimore
MUSC Hollings Cancer Center, Charleston
Georgia Cancer Center Augusta University, Atlanta
The University of Alabama at Birmingham, Birmingham
Corewell Health, Grand Rapids
University of Arkansas for Medical Sciences, Little Rock
OU Health Stephenson Cancer Center, Oklahoma City
UCLA, Los Angeles
Hoag Memorial Hospital, Newport Beach
Fred Hutchinson Cancer Center, Seattle
Dana Farber Cancer Institute, Boston
Volastra Therapeutics, Inc.
INDUSTRY